US: IBDoc® is not available for sale in the US.
Health Canada License: 98903, Device class: 3
BÜHLMANN was nominated to receive the Swiss Medtech Award for 2018 for the IBDoc® calprotectin smartphone-based rapid test
About Swiss MEDTECH
Swiss Medtech was established on 12 June 2017 following the merger of two national medtech organizations, FASMED and Medical Cluster. The new association represents the interests of the Swiss medtech industry. The aim is to maintain international competitiveness, innovative capacity, and to strengthen the domestic market.
Swiss Medtech is committed to promoting Switzerland as a leading scientific workplace and centre of research by providing targeted training and further education programmes, symposiums, export-promoting services, and supportive measures for entrepreneurship. The Association also contributes significantly to ensuring quality-oriented health care with fair reimbursement rates and advanced innovation funding for patient well-being.